Clinical experience with downsized lower energy output implantable cardioverter defibrillators

被引:4
作者
Boriani, G
Frabetti, L
Biffi, M
Sallusti, L
机构
[1] Univ Bologna, Inst Cardiol, I-40138 Bologna, Italy
[2] Guidant Italia, Milan, Italy
[3] KH, Vienna, Austria
[4] Rigshosp, DK-2100 Copenhagen, Denmark
[5] CHU Caen, F-14000 Caen, France
[6] Hop Cardiol, F-59037 Lille, France
[7] Ak St Georg, Hamburg, Germany
[8] HZ Lahr, Baden, Switzerland
[9] Kerckhoff Klin, Bad Nauheim, Germany
[10] RD Isar, Munich, Germany
[11] Univ Frankfurt, D-6000 Frankfurt, Germany
[12] Uni Hosp Magdeburg, Magdeburg, Germany
[13] Uni Klin, Mainz, Germany
[14] Uni Klin, Marburg, Germany
[15] Univ Munster Klin, Munster, Germany
[16] S Orsola Hosp, Bologna, Italy
[17] Univ Lund Hosp, S-22185 Lund, Sweden
[18] Southampton Gen Hosp, Southampton, Hants, England
关键词
cardioverter-defibrillators; defibrillation threshold; ventricular tachyarrhythmias;
D O I
10.1016/S0167-5273(98)00239-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and sturdy objective: Technical improvements in cardioverter defibrillators technology has resulted in decrease in can size coupled with improved electrodes technology. A decrease in maximum energy output allows further decrease in device size. The aim of this study was to evaluate the feasibility of a single lead transvenous implant employing a downsized cardioverter-defibrillator (volume 59 cm(3)), with a related decrease in maximum energy output (29-31 joules as stored energy and 25-27 joules as delivered energy). Methods and results: Fifty-five patients with ventricular tachyarrhythmias were enrolled in 17 European institutions for implantation. At implantation step-down defibrillation threshold (DFT) was determined and the device was implanted only if a safety margin greater than or equal to 10 joules was maintained between DFT and maximum programmable output. Implantation was performed in 54 of the 55 referred patients (98%) in a single electrode-device configuration. Step-down DFT testing was performed in 44 patients (43 finally implanted) and DFT was 7.77+/-4.41 joules (range 3-20). In 20 of the tested patients (45%) DFT was less than or equal to 5 joules, in 26 patients (59%) was less than or equal to 8 joules and in 34 patients (77%) it was less than or equal to 10 joules. No differences were found in DFT comparing patients with left ventricular ejection fraction less than or equal to or >40% or patients treated or not with antiarrhythmic drugs or beta-blockers. Mean implant duration was 85+/-34 min. Conclusions: Employing a downsized cardioverter defibrillator, successful transvenous implantation can be achieved in 98% of the patients, with maintenance of adequate defibrillation safety margins despite a reduction in stored energy to 29 joules. Implantation of the device with a lead-alone configuration allows short implant times and few perioperative complications. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:261 / 266
页数:6
相关论文
共 21 条
[1]  
AURICCHIO A, 1996, PACE, V19, P521
[2]  
AUSTIN E, 1994, IMPLANTABLE CARDIOVE, P327
[3]   A SIMPLIFIED, SINGLE-LEAD UNIPOLAR TRANSVENOUS CARDIOVERSION-DEFIBRILLATION SYSTEM [J].
BARDY, GH ;
JOHNSON, G ;
POOLE, JE ;
DOLACK, GL ;
KUDENCHUK, PJ ;
KELSO, D ;
MITCHELL, R ;
MEHRA, R ;
HOFER, B .
CIRCULATION, 1993, 88 (02) :543-547
[4]   Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function? [J].
Block, M ;
Hammel, D ;
Bocker, D ;
Borggrefe, M ;
Breithardt, G .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (5A) :62-68
[5]  
Block M, 1995, CARDIAC ELECTROPHYSI, P1412
[6]  
BOCKER D, 1993, J AM COLL CARDIOL, V21, P1638
[7]  
DUFFIN EG, 1994, IMPLANTABLE CARDIOVE, P751
[8]   ANTIARRHYTHMIC DRUGS IN PATIENTS WITH AN AUTOMATIC IMPLANTABLE DEFIBRILLATOR [J].
FARRE, J ;
ASSO, A ;
ROMERO, J ;
CABRERA, JA ;
ZAYAS, R ;
NEGRETE, A ;
FIDALGO, M .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1995, 18 (03) :579-591
[9]   ELECTROPHYSIOLOGICAL LABORATORY, ELECTROPHYSIOLOGIST-IMPLANTED, NONTHORACOTOMY-IMPLANTABLE CARDIOVERTER/DEFIBRILLATORS [J].
FITZPATRICK, AP ;
LESH, MD ;
EPSTEIN, LM ;
LEE, RJ ;
SIU, A ;
MERRICK, S ;
GRIFFIN, JC ;
SCHEINMAN, MM .
CIRCULATION, 1994, 89 (06) :2503-2508
[10]   Impact at the implantable defibrillator on mortality: The axiom of overall implantable cardioverter-defibrillator survival [J].
Fogoros, RN .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 :57-61